Pelthos Therapeutics
PTHS
5 hedge funds and large institutions have $290K invested in Pelthos Therapeutics in 2024 Q2 according to their latest regulatory filings, with 4 funds opening new positions, increasing their positions, 1 reducing their positions, and closing their positions.
400% more funds holding
Funds holding: 1 → 5 (+4)
0.12% less ownership
Funds ownership: 0.51% → 0.38% (-0.12%)
56% less capital invested
Capital invested by funds: $660K → $290K (-$370K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$31.5K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$320 |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$17 |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$17 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AFM
Anson Funds Management
Dallas,
Texas
|
-$85.6K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AFM
1
Anson Funds Management
Dallas,
Texas
| $265K | -$85.6K | -5,086 | -20% |
|
|
2
Citadel Advisors
Miami,
Florida
| $24.7K | +$31.5K | +1,871 | New |
|
|
3
UBS Group
Zurich,
Switzerland
| $246 | +$320 | +19 | New |
|
|
4
Bank of America
Charlotte,
North Carolina
| $12 | +$17 | +1 | New |
|
|
TRCT
5
Tower Research Capital (TRC)
New York
| $8 | +$17 | +1 | New |
|
PTHS Hedge Fund Activity: Q2 2024 in Review
5 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Pelthos Therapeutics (PTHS) for Q2 2024, worth a combined $290K — down 56% from $660K a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new PTHS positions and 0 closed out — a net gain of 4 holders — while 0 added to existing stakes and 1 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $31.5K. The largest seller was Anson Funds Management, cutting an estimated $85.6K.
- 5 institutional investors held Pelthos Therapeutics (PTHS) as of Q2 2024, up from 1 in Q1 2024.
- Funds reported $290K of Pelthos Therapeutics stock for Q2 2024, down 56% quarter-over-quarter.
- 4 funds opened new Pelthos Therapeutics positions in Q2 2024 and 0 closed out, a net change of +4 holders.
- The largest Pelthos Therapeutics buyer in Q2 2024 was Citadel Advisors, an estimated $31.5K added.
- The largest Pelthos Therapeutics seller in Q2 2024 was Anson Funds Management, an estimated $85.6K sold.
Based on aggregated 13F filings for Q2 2024.